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ABSTRACT
Introduction To report the observations of point- of- care 
(POC) glycated hemoglobin (HbA1c) testing in people with 
non- diabetic hyperglycemia (NDH; HbA1c 42–47 mmol/
mol (6.0%–6.4%)), applied in community settings, within 
the English National Health Service Diabetes Prevention 
Programme (NHS DPP).
Research design and methods A service evaluation 
assessing prospectively collected national service- level 
data from the NHS DPP, using data from the first referral 
received in June 2016–October 2018. Individuals were 
referred to the NHS DPP with a laboratory- measured 
HbA1c in the NDH range and had a repeat HbA1c 
measured at first attendance of the program using 
one of three POC devices: DCA Vantage, Afinion or A1C 
Now+. Differences between the referral and POC HbA1c 
and the SD of the POC HbA1c were calculated. The 
factors associated with the difference in HbA1c and the 
association between POC HbA1c result and subsequent 
attendance of the NHS DPP were also evaluated.
Results Data from 73 703 participants demonstrated a 
significant mean difference between the referral and POC 
HbA1c of −2.48 mmol/mol (−0.23%) (t=157, p<0.001) 
with significant differences in the mean difference 
between devices (F(2, 73 700)=738, p<0.001). The SD of 
POC HbA1c was 4.46 mmol/mol (0.41%) with significant 
differences in SDs between devices (F(2, 73 700)=1542, 
p<0.001). Participants who were older, from more 
deprived areas and from Asian, black and mixed ethnic 
groups were associated with smaller HbA1c differences. 
Normoglycemic POC HbA1c versus NDH POC HbA1c values 
were associated with lower subsequent attendance at 
behavioral interventions (58% vs 67%, p<0.001).
Conclusion POC HbA1c testing in community settings 
was associated with significantly lower HbA1c values 
when compared with laboratory- measured referrals. 
Acknowledging effects of regression to the mean, we 
found that these differences were also associated with 
POC method, location, individual patient factors and time 
between measurements. Compared with POC HbA1c 
values in the NDH range, normoglycemic POC HbA1c 
values were associated with lower subsequent intervention 
attendance.
INTRODUCTION
In 2016, the Healthier You: National Health 
Service Diabetes Prevention Programme (NHS 
DPP) was developed to prevent or delay onset 
of type 2 diabetes in adults in England identi-
fied with non- diabetic hyperglycemia (NDH) 
(glycated hemoglobin (HbA1c) 42–47 mmol/
mol (6.0%–6.4%) or fasting plasma glucose 
(FPG) 5.5–6.9 mmol/L).1 The NHS DPP delivers 
behavioral interventions based on guidance 
from the National Institute for Health and Care 
Excellence (NICE) via provider organizations 
who used serial point- of- care (POC) HbA1c 
testing to track responses to interventions.2
Significance of this study
What is already known about this subject?
 ► Point- of- care (POC) glycated hemoglobin (HbA1c) 
devices are increasingly used in community settings 
and may vary in performance.
What are the new findings?
 ► POC HbA1c measurements within the English 
National Health Service Diabetes Prevention 
Programme were significantly lower when com-
pared with referral HbA1c measurements. These 
differences were associated with the POC assay, its 
location of use, individual patient factors (including 
deprivation status, age and ethnicity) and the time 
between measurements.
How might these results change the focus of 
research or clinical practice?
 ► Practitioners using POC HbA1c devices to assess 
people with non- diabetic hyperglycemia should 
be aware of factors associated with differences in 
HbA1c values but crucially the impact of these val-
ues on interpretation and on subsequent attendance 
at behavioral interventions.
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Routine internal monitoring of the program indicated a 
significant mean difference between laboratory- measured 
HbA1c values obtained on referral to the program (under-
taken by referring general practices) and values obtained on 
first attendance of the program, where HbA1c was remea-
sured using a POC device.
Differences in an HbA1c level measured at two time points 
may reflect regression to the mean, a genuine biological 
change, or variation in the testing methodology used. The 
demographic, individual patient or assay- related factors 
that affect change in HbA1c outside of the diabetes range 
are not well- studied. This knowledge is vital, however, if 
serial measurements are used in people with NDH, which 
represents a narrow clinical range of interest, and where 
small changes in HbA1c have the potential to diagnose type 
2 diabetes at one extreme or to declassify NDH status at the 
other.
Using data from the first 29 months of the NHS DPP, we 
aimed to
1. Determine if there were significant differences be-
tween laboratory- measured HbA1c and subsequent 
POC HbA1c measurements across all devices and test-
ing pathways in the NHS DPP.
2. Identify modifiable and non- modifiable factors asso-
ciated with observed differences between laboratory- 
measured HbA1c and POC measured HbA1c in the 
NHS DPP.
3. Assess the association between POC remeasurements 
of HbA1c and subsequent attendance of the NHS DPP.
The study does not attempt to assess the performance of 
POC devices in the measurement of HbA1c but rather to 
examine the implications of their use in a community setting 
as a follow- up to a laboratory HbA1c measurement.
RESEARCH DESIGNS AND METHODS
Study design
This study is a service evaluation in England assessing 
prospectively collected national service- level data from the 
NHS DPP using data from the first referral received in June 
2016 to October 2018.
Intervention
The NHS DPP delivers behavioral interventions encouraging 
weight loss in those overweight or obese, increased physical 
activity and healthier diets, through a minimum of 13 face- 
to- face group- based sessions, over at least 9 months, consti-
tuting at least 16 hours of contact time. Over this time period, 
interventions were delivered by one of four service providers 
selected as part of a national competitive procurement 
process: Reed Momenta Ltd (London, UK), ICS Health and 
Well- being (Leeds, UK), Ingeus UK Ltd (London, UK), and 
Living Well Taking Control LLP (Birmingham, UK).
Participants
Individuals with a test result indicating NDH within the 
previous 12 months, aged 18 years or over, not pregnant 
and not previously diagnosed with type 2 diabetes were 
identified from NHS Health Checks,3 general practice 
records or routine clinical practice. The majority of 
referrals included HbA1c results from laboratory testing, 
rather than FPG, although testing methodology was not 
stipulated. Individuals referred to the program were 
invited to attend an initial assessment (IA) during which 
further details of the program were provided, and partic-
ipants were assigned to a group for intervention delivery.
Data collection
Program providers were contractually required to collect 
a minimum dataset; age, sex, postcode, the referral 
HbA1c/FPG and optionally, weight, were recorded on 
referral; ethnicity, weight and height at IA. Providers 
were contractually required to assess HbA1c at IA if the 
referral HbA1c or FPG was assessed more than 3 months 
previously. This service evaluation involved assessment 
of anonymized data collected during routine service 
delivery; NHS England has published an information 
governance framework setting out the legal basis for 
data collection and data flows, ensuring that the service 
and its evaluation are delivered in compliance with data 
protection legislation.4
Sex was recorded as male, female or indeterminate. 
Recorded ages were grouped (to align with both NHS 
health checks and retirement age) into <40, 40–64, 65–74 
and 75+ years and self- reported ethnicity as white, Asian, 
black, mixed or other. Deprivation scores were obtained 
using lower super output area (derived from participant 
postcode) linked to the deprivation quintile from the 
Index of Multiple Deprivation. BMI was calculated for 
participants who had weight and height recorded at IA. 
All variables also include an unknown category where 
either the participant declined to give the relevant infor-
mation or a value was not recorded.
POC devices
An expert working group was established to advise on 
internationally stipulated minimum performance criteria 
for HbA1c within the program and provided more 
specific guidance around use of POC devices,5 including 
calibration to the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) reference 
measurement procedure, and that Medicines and Health-
care products Regulatory Authority guidance around 
the provision of a quality framework, including internal 
quality control and external quality assessment (EQA) to 
support POC delivery, be followed.6 EQA, a process by 
which individual analytical devices can be compared with 
a reference or other devices, captures device bias and, 
with serial assessment, changes in analytical performance 
over time for any single device. Deviation in EQA perfor-
mance can be investigated and resolved.
The four providers used HbA1c POC devices: DCA 
Vantage (Siemens Healthcare, Guildford, UK), Afinion 
(Abbott Diagnostics, Maidenhead, UK) or A1C Now+ 
(BHR Pharmaceutical, Nuneaton, UK). A ‘POC pathway’ 
was defined as the combination of the device used and 
the location where testing was performed, either a Lloyds 
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pharmacy (subcontracting arrangements used by two 
providers) or ‘in- house’ (a community venue where a 
provider delivered the intervention). Pathways are listed 
in table 1. Providers used the same device and pathway 
for each participant. Though not contractually required, 
in some individuals, providers undertook POC HbA1c 
within 3 months of the referral HbA1c.
Outcomes
The primary outcomes were the difference in HbA1c 
between laboratory- measured HbA1c and subsequent 
POC measured HbA1c and SD of POC measured HbA1c. 
The factors associated with the difference in HbA1c and 
the association between IA POC HbA1c and subsequent 
attendance were also evaluated.
The HbA1c difference between referral and IA and 
the SD of IA POC HbA1c was calculated for participants 
with a valid HbA1c recorded at both referral and IA. For 
a subgroup of participants with available data, the rela-
tionship between recorded HbA1c difference and weight 
change was examined. In those who had had sufficient 
time to attend, the relationship between IA POC HbA1c 
results and subsequent attendance at the group- based 
behavioral intervention sessions was studied by grouping 
individuals according to IA POC HbA1c values as normo-
glycemic (<42 mmol/mol), NDH (42.0–47.9 mmol/mol) 
and type 2 diabetes range (≥48 mmol/mol).
Statistical analysis
A paired t- test was used to test for differences between 
the mean referral and mean IA HbA1c, and a one- way 
analysis of variance was used to determine differences in 
the mean HbA1c change at IA. Where the null hypothesis 
for Bartlett’s test for equality of variances was rejected, 
Kruskal- Wallis equality of population rank test was also 
undertaken. Levene’s test was used to test equality of SDs 
between pathways.
Mixed- effects linear regression models were used to 
identify factors associated with differences in HbA1c. In 
model 1, pathway, referral HbA1c, time (days) between 
referral HbA1c and IA HbA1c, and participant char-
acteristics (age, sex, ethnicity and deprivation) were 
considered as fixed effects, and local referral area was 
considered as a random effect with the contribution of the 
random effect quantified using the intraclass correlation 
coefficient (ICC). Local referral areas are only associated 
with a single provider and therefore incorporate the same 
facilities and facilitators used by that provider. Variation 
between the four providers was directly accounted for by 
a fixed effect in the model. Model 2 substituted pathway 
for device, with other variables remaining the same. 
Model 3 included weight change between referral and 
IA. A mixed- effects logistic regression model was used 
to identify factors associated with attendance of at least 
one intervention session following IA and was applied to 
the subgroup who had had at least 6 months to attend 
an intervention session. Pathway, participant character-
istics (including BMI at IA) and POC HbA1c grouping 
at IA were considered as fixed factors and local referral 
area as a random effect. Only participants from the given 
subgroup for whom all data fields were complete were 
included in the regression analyses.
Sensitivity analyses were conducted on the regression 
models using multiple imputation, employing the multi-
variate chained equations approach to impute missing 
data and then comparing the results to the primary anal-
yses.7 We used the fraction of missing information as a 
rule of thumb to estimate the number of imputations 
needed and imputed missing values for age, deprivation, 
sex, ethnicity and BMI. All participants had recorded 
data for pathway, local referral area, referral HbA1c and 
IA HbA1c.
Statistical significance was defined as a p value of <0.05. 
Where there were multiple comparisons, a post hoc 
Bonferroni correction was applied. CIs were set at 95%. 
All data were analyzed using STATA V.15.
RESULTS
HbA1C at referral
Overall, 73 703 participants had an HbA1c measurement 
at both referral and IA. Characteristics of participants are 
provided in table 2; 44% of participants were male; the 
mean age was 64 (SD 12) years; and 20% were of black, 
Asian, mixed or other ethnicity; 65% were white; and 
16% were unknown. There was broadly equal represen-
tation from all deprivation quintiles. The mean HbA1c at 
referral was 43.7 (SD 1.5) mmol/mol (6.1% (SD 0.14%)). 
Though statistically significant differences, there were no 
clinically meaningful differences in the mean referral 
HbA1c by pathway, ranging from 43.6 (SD 1.5) mmol/
mol (6.1 (SD 0.14) %) to 43.8 (SD 1.5) mmol/mol (6.2 
(SD 0.14) %). Data were missing for age (<0.01%), sex 
(0.6%), ethnicity (15.7%) and deprivation (0.4%). There 
were no missing data for referral HbA1c, IA HbA1c and 
pathway and device.
HbA1C at IA
The mean (SD) number of days between HbA1c 
measurements was 203 (120) days. The mean IA HbA1c 
was 41.2 (SD 4.46) mmol/mol (5.9 (SD 0.41) %), a signif-
icant difference of −2.48 mmol/mol (SD −0.23%) from 
the mean referral HbA1c (t=157, p<0.001). Significant 
Table 1 Provider pathways and devices used by the 
National Health Service (NHS) Diabetes Prevention 
Programme
Provider pathway Device
Living Well Taking Control—provider 1 Afinion
ICS Health and Well- being—provider 2 DCA Vantage
Reed via Lloyds Pharmacy—provider 3 A1c Now+
Reed in- house pathway—provider 3 A1c Now+
Ingeus via Lloyds Pharmacy—provider 4 A1c Now+
Ingeus in- house pathway—provider 4 DCA Vantage
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differences were observed for all pathways and for all 
devices (table 2). Mean differences were significantly 
different between pathways (F(5, 73 697)=374; p<0.001) 
and between devices (F(2, 73 700)=738; p<0.001), with 
significant differences for 11 of the 15 pairwise combi-
nations of pathways and all pairwise combinations of 
devices (online supplemental tables S1 and S2). There 
were significant differences in the SD of the HbA1c at 
IA between pathways (F(5, 73 697)=598.9; p<0.001) and 
devices (F(2, 73 700)=1541.8; p<0.001) (table 2). There 
were no significant differences in the SD between path-
ways using the same device. There were significant differ-
ences between the DCA Vantage and A1c Now+ devices 
(F(1, 62 133)=2186.6; p<0.001), Afinion and A1c Now+ 
devices F(1, 42 832)=1548.4; p<0.001) and Afinion and 
DCA Vantage devices F(1, 42 502)=68.0; p<0.001).
Factors associated with the change in HbA1c from referral to 
IA
Univariate analyses of outcomes are provided in table 2. 
HbA1c differences between referral and IA measure-
ments became larger as the number of days between 
measurements increased from the category of <28 days 
up to the category of 84–111 days, then reduced as the 
number of days increased further (figure 1A). The SD of 
the HbA1c at IA increased as the number of days between 
measurements increased (figure 1B). Regression analysis 
indicated that for each 1.0 mmol/mol higher value of 
referral HbA1c, there was a corresponding 0.2 mmol/
mol greater difference between referral and IA POC 
HbA1c (table 3). The POC pathway had a significant 
association with observed HbA1c difference; using the 
ICS Health and Well- being (DCA Vantage) pathway 
(which had the greatest number of participants) as a 
reference, no difference in the magnitude of reduction 
was observed for the Ingeus (DCA Vantage) pathway, but 
all other pathways were associated with a greater HbA1c 
difference. Measurements from participants who were 
older or from more deprived areas were associated with 
smaller HbA1c differences, but there was no effect of sex. 
Relative to white groups, Asian, black and mixed ethnic 
groups had a smaller HbA1c difference. Clustering by 
local referral area made a proportionally small contribu-
tion to the outcomes (ICC 3.7% (2.6%–5.4%)). In model 
2, the device was found to be significantly associated with 
HbA1c difference; Afinion and A1C Now+ devices were 
both associated with larger differences compared with 
the DCA Vantage device (online supplemental table S3).
Association of HbA1c change with weight
A subset of 20 576 participants had available weight 
measurements at referral and IA. At referral, the mean 
weight was 81.7 (SD 18.3) kg and the mean HbA1c was 
43.6 (SD 1.5) mmol/mol (6.1 (0.14) %). The mean 
weight change between referral and IA was +1.4 kg 
(t=39.8, p<0.001), with 56% of the participants gaining 
weight, 17% remaining the same and 27% losing weight. 
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those with recorded weight measures was −3.13 mmol/
mol (−0.29%) (t=95, p<0.001). A reduction in the mean 
HbA1c was observed across all weight change categories 
(gaining weight/remaining the same/losing weight). 
Incorporating weight into the regression model (model 
3), we found that change in the referral weight had a 
Figure 1 (A) Mean HbA1c change between laboratory- measured HbA1c at referral and POC remeasurement at IA by the 
number of days between measurements and device. (B) SD of IA POC remeasurement HbA1c by the number of days between 
HbA1c measurements and device. HbA1c, glycated hemoglobin; IA, initial assessment; POC, point- of- care.
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Table 3 Difference between laboratory- measured HbA1c at referral and point- of- care remeasurement at IA by pathway 
(N=61 623), mixed- effects linear regression
Coefficient 95% lower CI 95% upper CI SE P value
Referral HbA1c reading −0.2 −0.22 −0.18 0.01 <0.001
Pathway
  ICS Health and Well- being (DCA 
Vantage)
  Ingeus Inhouse (DCA Vantage) −0.34 −0.93 0.24 0.3 0.25
  Ingeus Lloyds (A1c Now+) −2.18 −2.77 −1.6 0.3 <0.001
  Living Well Taking Control (Afinion) −0.85 −1.37 −0.32 0.27 <0.001
  Reed Inhouse (A1c Now+) −0.98 −1.58 −0.39 0.3 <0.001
  Reed Lloyds (A1c Now+) −1.83 −2.57 −1.09 0.38 <0.001
Sex
  Male
  Female 0.00 −0.06 0.07 0.03 0.993
  Indeterminate 0.82 −0.37 2.01 0.6 0.18
Age group (years)
  <40
  40–64 0.34 0.16 0.52 0.09 <0.001
  65–74 0.38 0.19 0.56 0.1 <0.001
  75+ 0.41 0.22 0.61 0.1 <0.001
Ethnicity
  White
  Asian 0.36 0.25 0.47 0.06 <0.001
  Black 0.93 0.8 1.07 0.07 <0.001
  Mixed 0.63 0.38 0.88 0.13 <0.001
  Other 0.15 −0.17 0.47 0.16 0.35
Index of multiple deprivation quintile
  1 (most deprived)
  2 −0.11 −0.22 −0.01 0.05 0.03
  3 −0.19 −0.29 −0.09 0.05 <0.001
  4 −0.28 −0.39 −0.17 0.05 <0.001
  5 (least deprived) −0.34 −0.45 −0.23 0.06 <0.001
Number of days between referral and IA HbA1c
  <28
  28–55 −0.72 −1.06 −0.38 0.17 <0.001
  56–83 −0.98 −1.31 −0.65 0.17 <0.001
  84–111 −1.51 −1.83 −1.2 0.16 <0.001
  112–139 −1.31 −1.63 −0.99 0.16 <0.001
  140–167 −1.31 −1.63 −0.99 0.16 <0.001
  168–195 −1.17 −1.5 −0.85 0.17 <0.001
  196–223 −1.09 −1.41 −0.76 0.17 <0.001
  224–251 −1.12 −1.45 −0.79 0.17 <0.001
  252–279 −1.06 −1.39 −0.73 0.17 <0.001
  280–307 −0.99 −1.33 −0.66 0.17 <0.001
  308–335 −0.89 −1.23 −0.55 0.17 <0.001
  336–363 −0.67 −1.01 −0.33 0.17 <0.001
  363–739 −0.81 −1.13 −0.49 0.16 <0.001
Continued
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small but significant positive association with the change 
in HbA1c; for each 1 kg increase in weight, there was 
a 0.06 mmol/mol smaller decrease in HbA1c (online 
supplemental table S4). The ICC was 1.8% (0.9%–3.7%).
Association between POC HbA1c result and attendance at 
subsequent intervention session
Studying only those who had sufficient time to attend an 
intervention session (46,894), 48% of HbA1c measure-
ments were in the normoglycemic range, 46% in the 
NDH range and 6% in the type two diabetes range. Partic-
ipants with an IA POC HbA1c in the normoglycemic 
range had significantly lower subsequent attendance at 
an intervention session compared with those in the NDH 
range (58% vs 67%; p<0.001). Logistic regression anal-
ysis indicated that participants who were older, up to 74 
years, female, from less deprived areas and with a higher 
BMI, were more likely to attend a subsequent interven-
tion session. It also confirmed lower attendance for those 
with IA POC HbA1c in the normoglycemic range, even 
after adjusting for other factors (table 4). The ICC was 
26.1% (18.3%–35.8%).
Sensitivity analyses conducted by rerunning the regres-
sion models using imputed data showed no changes in 
direction and magnitude of the associations (online 
supplemental tables S5–S8).
DISCUSSION
Summary of key findings
Data from 73 703 participants in the NHS DPP show 
significant reductions between referral laboratory- 
measured HbA1c and HbA1c remeasured using a POC 
device on first attendance of the program. Acknowl-
edging the effects of regression to the mean, we found 
that the magnitude of the reduction in HbA1c observed 
was associated with the POC device used, the POC 
testing pathway, individual participant factors, including 
age, ethnicity and social deprivation, and time between 
measurements. Furthermore, reductions in HbA1c were 
greater than concurrent weight change would suggest is 
attributable to behavior change, although it is possible 
that other behavioral modification, independent of 
weight change, and not captured in this study, were 
also associated with the mean HbA1c difference. POC 
HbA1c in the normoglycemic range was associated with 
lower subsequent intervention attendance. However, it 
is important to note that this study does not attempt to 
assess the accuracy of POC testing, but rather examines 
the implications of using POC in the NHS DPP.
Use of POC HbA1c devices
There is increasing interest in the use of POC diagnostics 
internationally, where the provision of results in real time 
might positively impact patient care.8 Despite reasonable 
POC HbA1c testing performance in laboratory method 
evaluations, performance has been variable in some 
research studies,9–11 although newer- generation analyzers 
have shown improved analytical performance.12 13 While 
the use of POC HbA1c in community settings has gener-
ated interest,14–18 performance of POC HbA1c away from 
highly regulated, specialist supported laboratories within 
the narrow NDH range remains unclear.
The NHS DPP does not generate contemporane-
ously measured POC and laboratory- measured HbA1c 
and cannot robustly validate POC device performance 
against a reference. However, significant differences in 
the mean HbA1c between referral and IA were demon-
strated for all pathways and devices. POC pathway and 
device had significant associations with the observed 
HbA1c difference, independent of other variables, 
including the time between measurements. The associ-
ation of higher referral HbA1c values with larger differ-
ences suggests regression to the mean. However, the 
mean HbA1c differences were significantly larger for all 
devices and pathways than the mean HbA1c differences 
between two laboratory HbA1c measurements as part of a 
previously published regional study, the Norfolk Diabetes 
Prevention Study.19 20 While regression to the mean is 
likely contributory, there is no obvious reason why the 
contribution should be so much greater for NHS DPP 
compared with the previous regional study, although the 
regional population was smaller, less ethnically diverse 
with less variation by age and over a shorter time period. 
One potential explanation for the observed differences 
in our study is the introduction of a significant negative 
bias (attributable to both pathway and device) when POC 
HbA1c testing was applied in the community setting.
Coefficient 95% lower CI 95% upper CI SE P value
  >730 −0.84 −1.72 0.03 0.45 0.06
  Constant 7.63 6.61 8.65 0.52 <0.001
Random- effects parameters Estimate SE 95% lower 95% upper
Local referral area: identity
  var(constant) 0.61 0.12 0.42 0.89
  var(Residual) 15.68 0.09 15.51 15.86
Likelihood- ratio test versus linear model: chi- bar- squared (01)=1619.49, p<0.001.
HbA1c, glycated hemoglobin; IA, initial assessment.
Table 3 Continued
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The significant differences in the SDs of IA POC HbA1c 
between pathways may reflect differences in the level 
of training of the user, location and transportation of 
devices, or other factors such as device maintenance and 
calibration, although the POC HbA1c device used was a 
significant independent factor with significant differences 
between all three devices, suggesting the underlying assay 
methodology was an important contributor.
Use of POC HbA1c assays in the NDH range
The IFCC task force (TF) published performance criteria 
for HbA1c methods using total allowable error, a concept 
Table 4 Attendance of at least one intervention session in the National Health Service (NHS) Diabetes Prevention Programme 
after IA (N=33 544), mixed- effects logistic regression
OR 95% lower CI 95% upper CI P value
Pathway†
  ICS Health and Well- being (DCA Vantage)
  Living Well Taking Control (Afinion) 2.17 0.99 4.75 0.05
  Reed Inhouse (A1c Now+) 1.67 0.72 3.86 0.23
  Reed Lloyds (A1c Now+) 1.62 0.65 4.05 0.3
Sex
  Male
  Female 1.07 1.02 1.12 0.01
  Indeterminate 0.76 0.34 1.67 0.49
Age (years)
  <40
  40–64 1.64 1.43 1.88 <0.001
  65–74 2.37 2.06 2.73 <0.001
  75+ 1.9 1.64 2.2 <0.001
Ethnicity
  White
  Asian 1.09 1 1.18 0.05
  Black 1.3 1.18 1.44 <0.001
  Mixed 1.17 0.97 1.41 0.1
  Other 1.28 0.95 1.71 0.1
Index of multiple deprivation quintile
  1 (most deprived)
  2 1.17 1.09 1.26 <0.001
  3 1.29 1.2 1.4 <0.001
  4 1.33 1.23 1.44 <0.001
  5 (least deprived) 1.46 1.34 1.59 <0.001
BMI at IA
  Underweight/healthy
  Overweight 1.16 1.08 1.24 <0.001
  Obese 1.27 1.18 1.36 <0.001
HbA1c measurement at IA
  NDH (42.0–47.9 mmol/mol)
  Normoglycemic (<42 mmol/mol) 0.71 0.67 0.75 <0.001
  Diabetes (≥48 mmol/mol)* 0.32 0.28 0.35 <0.001
Random- effects parameters Estimate SE 95% lower CI 95% upper CI
Local referral area: identity
  var(constant) 1.16 0.27 0.74 1.84
Likelihood- ratio test versus logistic model: chi- bar- squared (01)=1851.98, p=<0.001.
*Participants with a HbA1c>51 mmol/mol are taken off the program and put on to type 2 diabetes treatment pathways.
†For Ingeus, the IA was spread across the first intervention session and was not comparable to other providers; therefore, it was not included in the 
regression analysis.
BMI, body mass index; HbA1c, glycated hemoglobin; IA, initial assessment; NDH, non- diabetic hyperglycemia.
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applied to the measurement of any analyte that encompasses 
both assay bias and imprecision.21 Total allowable error that 
falls within the biological variability of an analyte or below the 
threshold for a clinically meaningful change is considered 
acceptable. For HbA1c, a total allowable error of 5 mmol/
mol is an internationally derived performance standard 
for HbA1c assays.21 22 Laboratory environments are highly 
controlled with specialists available to identify and trouble-
shoot errors quickly. In contrast, POC application in commu-
nity settings may struggle with recognition of quality issues 
without adequate support.18 21–23 Indeed, in one study, many 
non- laboratory practitioners did not appreciate the impact 
of biological variability and analytical imprecision on small 
changes in HbA1c.24 However, while this allowable error is 
acceptable when applied to the values of HbA1c commonly 
encountered in diabetes care, it nearly completely traverses 
the NDH range, challenging meaningful interpretation 
despite appropriate quality frameworks.
The EurA1c study assessed both laboratory and POC 
devices in different countries and settings, using the 5 mmol/
mol total allowable error criteria set by the IFCC TF.25 Data 
from the most recent round of this study showed a mean bias 
of +0.5 mmol/mol and coefficient of variation (CV) of 4.1% 
in the UK. The Afinion device reported a bias of −1.7 mmol/
mol and CV of 3.3% and the DCA Vantage device reported a 
bias of −0.6 mmol/mol and CV of 3.7%. The A1CNow device 
was not studied. These data reflect observations in the NHS 
DPP and suggest that bias of devices within the NHS DPP lie 
within the allowable error.
Clinical implications of using POC HbA1c devices
The use of HbA1c to track responses to interventions in those 
with NDH has not previously been evaluated in terms of reli-
ability of results or effects on behavior. It has been suggested 
that the immediacy of POC HbA1c results may have benefi-
cial effects on motivation and behavior.26 27 However, in this 
context, POC HbA1c testing in the NHS DPP moved a large 
proportion of people into the normoglycemic range, which 
in turn was associated with reduced subsequent attendance, 
although regression to the mean may have accounted for 
some of this effect, irrespective of the methodology used for 
retesting HbA1c. However, it is possible that other behav-
ioral changes not captured in this study may have influ-
enced participants’ decisions not to continue to attend the 
program.28
HbA1c measurements within the NHS DPP were only used 
to assess response to the intervention and not for diagnosis. A 
POC HbA1c value in the diabetes range did lead to a repeat 
laboratory- measured HbA1c value, but POC HbA1c values 
in the normoglycemic range were not repeated. The risk of 
a delayed diagnosis of type 2 diabetes resulting from lower 
POC HbA1c values within the NHS DPP should be miti-
gated by the routine application of NICE guideline PH38,2 
which recommends annual reassessment of glycemic status 
for people with NDH. Annual rechecks of HbA1c in those 
with NDH in England will also be incentivized in future via 
general practice pay- for- performance.29
The same POC HbA1c device and pathway was used 
for each individual to track response to the intervention, 
so at cohort level, mean changes in HbA1c preinterven-
tion/postintervention provided a useful marker of overall 
program effectiveness, irrespective of any potential negative 
bias and higher variability.30
EQA is a reliable mechanism for identifying assay drift and 
for identifying poor performance beyond total allowable 
error, although this relies on the ability to identify and resolve 
quality issues, which may be challenging for non- specialists.24 
Some national schemes where POC HbA1c has been imple-
mented in standardized community locations have had some 
success, though performance is variable despite intensive 
education and not all devices can undergo EQA.23 31
Other factors associated with HbA1c change
Other significant associations in the change in HbA1c include 
age (with those under 40 years with the greatest decrease), 
ethnicity (Asian, black and mixed participants have a signifi-
cantly smaller decrease compared with white participants), 
and socioeconomic status (with the least deprived having 
the greatest decrease). The change in HbA1c varied by the 
number of days between tests, with the HbA1c difference 
between referral and IA becoming larger from the category 
of <28 days up to the category of 84–111 days and then some 
decrease. This could be consistent with people modifying 
their behavior initially after diagnosis of NDH (assuming at 
referral) and then lapsing. It is possible that the association 
between measurement change and some of the aforemen-
tioned parameters relates to differences in the extent of 
behavior change following referral/diagnosis of NDH and 
prior to attendance at IA. However, using weight change 
between referral and IA as a surrogate for behavior change, 
which shows more weight gain than weight loss, suggests 
against this.
Limitations
A limitation to the current analysis is that it is not possible to 
fully determine the extent of regression to the mean. The 
HbA1c reductions seen in these analyses were certainly much 
larger than those seen in a study applied to a very similar but 
smaller homogeneous population where repeat values were 
also assessed after an interval,19 20 suggesting an impact of 
additional contributors in the current analyses.
We assumed all referral HbA1c values were laboratory- 
measured, but a small proportion, although not routine prac-
tice in the UK, may have been POC- measured. Differences 
in mean HbA1c reduction may also reflect variability in the 
referral HbA1c values from different laboratory methods, 
which were not harmonized across the program, but are all 
assumed to be IFCC- calibrated.
There was a large variation in time between referral and IA. 
However, associations between HbA1c change and pathway 
and device were independent of time elapsed in the regres-
sion analyses. We were not able to formally assess bias of POC 
methods but used regression models to demonstrate that 
devices and pathways had associations with observed HbA1c 
differences.
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Device selection was left to the providers who were 
supplied with guidance around expected minimum 
performance criteria.
CONCLUSION
In summary, we show that a variety of modifiable and non- 
modifiable factors are associated with differences between 
laboratory- measured HbA1c in the NDH range and subse-
quent POC measurements in the NHS DPP, including POC 
device, but also how it is used and implemented (POC 
pathway). Critically, we show that the difference in measured 
HbA1c may indicate values in the normoglycemic range at 
IA and that this is associated with a reduction in subsequent 
attendance at diabetes prevention intervention sessions. We 
propose that particular attention be paid to the modifiable 
factors identified in this analysis, such as the POC device 
selected and pathway of implementation, as the observed 
changes in some cases have the potential to alter subsequent 
participant engagement with the program.
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